Home | Contact Us

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Recent News

bioTheranostics’ Prostate Cancer Index Predicts Risk for Prostate Cancer Recurrence

bioTheranostics Adds Chief Medical Officer & Vice President of Medical, Clinical & Regulatory Affairs

Prospective Study Shows that Therapy Guided by bioTheranostics’ CancerTYPE ID®  Molecular Test Improves Survival in Cancer of Unknown Primary Patients

Recent Publications

Medical Laboratory Observer:
Under Richard Ding’s direction, bioTheranostics focuses on biomarkers to aid in cancer treatment

Journal of Clinical Oncology:
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute

ASCO Post:
Gene Profiling–guided Therapy May Improve Survival in Patients with Carcinoma of Unknown Primary

CEOCFO Magazine:
With a Family of Diagnostic Tests Including Its CancerTYPE ID® Molecular Classifier That Can Predict the Tumor Type in Metastatic Cancer Patients, bioTheranostics Is at the Forefront of Diagnostic Innovation in Personalized Medicine

 

bioTheranostics develops and provides innovative oncology tests to support targeted disease management.

CancerTYPE ID® is a molecular test that uses the differential expression of 92 genes to aid in the determination of tumor site of origin.
Learn More >

Breast Cancer IndexSM is a prognostic biomarker that provides quantitative assessment of the likelihood of distant recurrence in patients diagnosed with estrogen receptor-positive, lymph node-negative breast cancer.
Learn More >

PRÉCIS® Precision Medicine by bioTheranostics
Includes biomarker profiles for non-small cell lung and colorectal cancer that detect clinically relevant tumor biomarkers.
Learn More >

© 2013 bioTheranostics. All rights reserved.
Client Services (877) 886-6739
Privacy Policy  |  Site Map  |  Speaker Bureau |  webmail